Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes

European Heart Journal

Volumn 23, Issue 19, 2002, Pages 1538-1545

  James, Stefan ^a   Armstrong, P ^b   Califf, R ^c   Husted, S ^d   Kontny, F ^e   Niemminen, M ^f   Pfisterer, M ^g   Simoons, M L ^h   Wallentin, L ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF ALBERTA   (Canada)

^c DUKE UNIVERSITY   (United States)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^f HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^g UNIVERSITY HOSPITAL BASEL   (Switzerland)

^h ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Angina; Coagulation; Heparin; Myocardial infarction

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; CREATINE KINASE MB; DALTEPARIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCERYL TRINITRATE; HEPARIN;

ADULT; AGED; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FIBRINOLYTIC THERAPY; HEMATEMESIS; HEMATURIA; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE; THROMBOCYTOPENIA;

EID: 0036800366     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.2002.3257     Document Type: Article

References (19)

1. Frisc study group. Fragmin during instability in coronary artery disease (FRISC) study group. Low molecular weight heparin during instability in coronary artery disease. Lancet 1996; 347: 561-8.
2. Eikelboom JW, Anand SS, Malmberg K. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: A meta-analysis. Lancet 2000; 355: 1936-42.
3. Antman EM, Cohen M, Radley D et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. Circulation 1999; 100: 1602-8.
4. EPIC investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 1994; 330: 956-61.
5. The CAPTURE investigators. Randomized placebo controlled trial of abciximab before and during coronary intervention in refractory unstable angina. Lancet 1997; 349: 1429-35.
6. The EPILOG investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during coronary revascularization. The EPILOG Investigators. N Engl J Med 1997; 336: 1689-96.
7. GUSTO IV ACS-investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outome in patients with acute coronary syndromes without early coronary revascularization: The GUSTO IV-ACS randomized trial. Lancet 2001; 357: 1915-24.
8. PRISM PLUS investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med 1998; 338: 1488-97.
9. PURSUIT investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med 1998; 339: 436-43.
10. Boersma E, Harrington RA, Moliterno DJ et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: A meta-analysis of all major randomised clinical trials. Lancet 2002; 359: 189-98.
11. Braunwald E, Antman EM, Beasley JW et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: Executive summary and recommendations. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on the management of patients with unstable angina). Circulation 2000; 102: 1193-209.
12. Bertrand ME, Simoons ML, Fox KA et al. Management of acute coronary syndromes: Acute coronary syndromes without persistent ST segment elevation; recommendations of the Task Force of the European Society of Cardiology. Eur Heart J 2000; 21: 1406-32.
13. Rao AK, Pratt C, Berke A et al. Thrombolysis in Myocardial Infarction (TIMI) Trial-phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988; 11: 1-11.
14. Ferguson JJ, Kereiakes DJ, Adgey AA et al. Safe use of platelet GP IIb/IIIa inhibitors. Eur Heart J 1998; 19 (Suppl D): D40-51.
15. Blankenship JC. Bleeding complications of glycoprotein IIb-IIIa receptor inhibitors. Am Heart J 1999; 138(4 Pt 2): 287-96.
16. Kereiakes DJ, Fry E, Matthai W et al. Combination enoxaparin and abciximab therapy during coronary intervention: 'NICE guys finish first'. J Invasive Cardiol 2000; 12 (Suppl A): 1A-5A.
17. Cohen EM, Theroux P, Frey, MJ. Anti-thrombotic combination using Tirofiban and Enoxaparin. The ACUTE II study. Circulation 2000; 102: Abstract 3982.
18. Kereiakes DJ, Kleiman NS, Fry E et al. Dalteparin in combination with abciximab during coronary intervention. Am Heart J 2001; 141: 348-52.
19. Cannon CP, Weintraub WS, Demopoulos LA et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001; 344: 1879-87.